MDMB-BINACA

Synthetic cannabinoid

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002693 | image = MDMB-BUTINACA_structure.png | image2 = | IUPAC_name = Methyl (2S)-2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate | CAS_number = 1971007-92-7 | PubChem = 129631792 | ChemSpiderID = 52085456 | UNII = | C=21 | H=29 | N=3 | O=3 | smiles = CC(C)(C)[C@@H](C(=O)OC)NC(=O)c1nn(CC2CCCCC2)c3ccccc13 | StdInChI = 1S/C21H29N3O3/c1-21(2,3)18(20(26)27-4)22-19(25)17-16-10-6-5-9-15(16)14-24(23-17)13-11-12-7-8-12/h5-6,9-10,12,18H,7-8,11,13-14H2,1-4H3,(H,22,25)/t18-/m0/s1 | StdInChIKey = }}

MDMB-BINACA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the CB1 receptor, which is part of the endocannabinoid system.

Chemical Structure and Properties

MDMB-BINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is methyl (2S)-2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate. The compound features a cyclohexylmethyl group attached to the indazole core, which is a common structural motif in many synthetic cannabinoids.

Structure of MDMB-BINACA

The molecular formula of MDMB-BINACA is C₂₁H₂₉N₃O₃, and it has a molecular weight of 371.48 g/mol. The compound is typically found as a white powder and is soluble in organic solvents.

Pharmacology

MDMB-BINACA acts as a potent agonist at the CB1 receptor, which is primarily located in the central nervous system. Activation of this receptor by MDMB-BINACA leads to effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis. These effects can include altered perception, mood changes, and impaired motor function.

The potency of MDMB-BINACA at the CB1 receptor is significantly higher than that of THC, which can lead to more pronounced effects and a higher risk of adverse reactions. Users of synthetic cannabinoids like MDMB-BINACA may experience severe side effects, including anxiety, paranoia, tachycardia, and hypertension.

Legal Status

Due to its potential for abuse and lack of medical use, MDMB-BINACA has been classified as a controlled substance in many countries. In the United States, it is listed as a Schedule I substance under the Controlled Substances Act. Similarly, it is controlled under the Misuse of Drugs Act 1971 in the United Kingdom.

Synthesis

The synthesis of MDMB-BINACA involves the reaction of an indazole core with a cyclohexylmethyl group and a dimethylbutanoate moiety. The process typically requires specialized knowledge in organic chemistry and access to controlled precursors.

Health Risks

The use of MDMB-BINACA is associated with significant health risks. Acute intoxication can lead to severe psychological and physiological effects, including hallucinations, seizures, and cardiovascular complications. Long-term use may result in dependence and withdrawal symptoms.

Related Pages

• Synthetic cannabinoids
• Cannabinoid receptor
• Designer drugs
• Drug policy